Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TNFSF11 | O14788 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.32 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1500435 | 0.89 | LMNA (0.39) | NPSR1MAPTHTTLMNATDP1 | |
| SCHEMBL11587654 | 0.80 | CYP3A4 (0.33) | MAPTLMNAALDH1A1F2GLA | |
| SCHEMBL11690916 | 0.76 | POLB (0.32) | NPSR1MAPTLMNA | |
| SCHEMBL9371729 | 0.76 | LMNA (0.38) | NPSR1MAPTHTTLMNATDP1 | |
| SCHEMBL3075874 | 0.75 | CYP3A4 (0.33) | MAPTLMNAALDH1A1F2GLA | |
| SCHEMBL23964443 | 0.75 | ELANE (0.41) | NPSR1MAPTHTTLMNATDP1 | |
| SCHEMBL22404886 | 0.75 | SMN1; SMN2 (0.37) | NPSR1MAPTHTTLMNATDP1 | |
| SCHEMBL33145 | 0.74 | ALDH1A1 (0.43) | NPSR1MAPTHTTLMNATDP1 | |
| SCHEMBL29286020 | 0.73 | LMNA (0.44) | LMNACYP1A2GAA | |
| SCHEMBL22428980 | 0.73 | MAPT (0.49) | NPSR1MAPTHTTLMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230340165-A1 | CROSS-LYNKED HYALURONIC ACID SYNTHESIS PROCESS | ISTITUTO GANASSINI S.P.A. DI RICERCHE BIOCHIMICHE (IT) | 2023-10-26 | — | — | US | disclosed |
| US-20170202980-A1 | METHOD FOR PRODUCING OPTICAL IMAGING CONTRAST AGENT AND OPTICAL IMAGING CONTRAST AGENT | CANON KABUSHIKI KAISHA (JP) | 2017-07-20 | — | — | US | disclosed |
| US-8153440-B2 | Methods for altering surface characteristics of microspheres | LUMINEX CORPORATION (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110086431-A1 | Methods for Altering Surface Characteristics of Microspheres | LUMINEX CORPORATION (US) | 2011-04-14 | — | — | US | disclosed |
| US-7867774-B2 | Methods for altering surface characteristics of microspheres | LUMINEX CORPORATION (US) | 2011-01-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170202980-A1 | METHOD FOR PRODUCING OPTICAL IMAGING CONTRAST AGENT AND OPTICAL IMAGING CONTRAST AGENT | ALB, FABP7, TTR | NPSR1 4282/4885MAPT 166/4885HTT 2911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.